INNOVATION FOR GOOD HEALTH INNOVATION FOR GOOD HEALTH

1

Care for Life Continuous Innovation Our pursuit of innovation never stops. From original invention to technical improvement, we enable lives to enjoy good health.

Pursuit of Excellence Win-Win Cooperation

CONTENTS

P2 Our Brand

P8 Our Vision

P12 Our Products & Services

P18 Our Teams

P22 Our Responsibility

Our Brand

01

We adhere to our brand concept “Innovation for Good Health”, care for life, continuous innovation, strive for excellence and win-win cooperation, we are the leading pharmaceutical and healthcare group in China.

Research and Development

Pharmaceutical Manufacturing

Healthcare Services

Pharmaceutical Distribution and Retail

Medical Diagnosis

Medical Devices

Company Profile Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196-SH, 02196-HK), established in 1994, is a leading company in China’s pharmaceutical and healthcare industry. Fosun Pharma strategically operates in several key sectors in the pharmaceutical and healthcare industry, including pharmaceutical manufacturing, distribution and retail, medical diagnosis and devices, and healthcare services, making contribution to public health. Fosun Pharma has a national-level technology center and an international R&D team, focusing on innovative R&D in therapeutic areas such as cardiovascular system, metabolism and alimentary tract, central nervous system, blood system, anti-tumor as well as anti-infective treatment. In future, Fosun Pharma will adhere to its brand concept of “Innovation for Good Health”, and insists on its business strategy of “organic growth with external expansion and integrated business operation”. We are dedicated to becoming a first class enterprise in major global healthcare market.

For more information, please visit

www.fosunpharma.com or follow us on WeChat (QR code):

INNOVATION FOR GOOD HEALTH

3

Board of Directors

4

Mr. Chen Qiyu

Mr. Yao Fang

Mr. Guo Guangchang

Mr. Wang Qunbin

Ms. Kang Lan

Executive Director Chairman

Executive Director Vice Chairman and CEO

Non-executive Director

Non-executive Director

Non-executive Director

Mr. Wang Pinliang

Mr. John Changzheng Ma

Mr. Zhang Weijiong

Mr. Cao Huimin

Mr. Jiang Xian

Mr. Wong Tin Yau Kelvin

Non-executive Director

Non-executive Director

Independent Nonexecutive Director

Independent Nonexecutive Director

Independent Nonexecutive Director

Independent Nonexecutive Director

INNOVATION FOR GOOD HEALTH

5

Brand Concept “Innovation for Good Health” —Our pursuit of innovation never stops. From original invention to technical improvement, we enable lives to enjoy good health.

Values

Care for Life

Continuous Innovation

We always care for human life, and endeavor to

We insist on independent R&D. Targeting at diseases that

improve the life quality of patients and their families.

endanger public health, we bring new possibilities for life

We cherish our living environment, and set green

and health via innovation breakthroughs.

and sustainable philosophy as guidelines for all

We create a a flexible and independent environment

business activities.

for scientific research, providing fertile ground for

We actively participate in and push forward actions

pharmaceutical innovation and technological improvement.

that benefit public health and environmental

We establish innovative management model and process,

improvement.

continuously improving the overall efficiency of corporate operation.

6

Pursuit of Excellence

Win-Win Cooperation

We put quality above everything else, establish

We practice diversified cooperation with

a production and management system with the

open-minded attitude, push forward business

highest international standards, and continuously

integration with common ideas, and promote

improve the manufacturing process, so as to

the synergy of industry values.

ensure quality and safety of our drugs.

We strive for the construction of a healthy

We continuously improve our capability of R&D

business eco-system, creating long-term values

and operation in pursuit of excellence.

for our employees, customers, shareholders and the society, so as to achieve sustainable development in the entire industry. INNOVATION FOR GOOD HEALTH

7

Our Vision

A first class enterprise in major global market

With global competitiveness

A leading enterprise to conduct internationalization in China

02 8

We are dedicated to becoming a first class enterprise in major global healthcare market

Combining China’s Growth Momentum with Global Resources Leverage its strength of well-established industry foundation, distribution network and investment experience, Fosun Pharma utilizes high quality capital, talents, brands and technologies around the globe to achieve all-round internationalization in products, markets, planning and operation, talents, capital and branding by following the business strategy of “organic growth with external expansion, integrated business operation”.

Europe United States China

Africa

To bring in high-caliber scientists team from developed countries such as the United States, and carry out R&D on generic drugs, biopharmaceutical drugs and innovative drugs in Shanghai, Chongqing, San Francisco and Taipei simultaneously To export the Artesunate series drugs in developing countries To market biosimilar drugs in China, and export chemical generic drugs and biopharmaceutical generic drugs to emerging and mature markets. To build on capabilities for the marketing of innovative drugs to global markets To establish the global presence and operational capability for medical devices To build up capability for integrating global healthcare resources

As of 30 June 2015, 13 APIs of Fosun Pharma received certifications from the

13

cGMP International Certification

U.S. FDA, EU Certification, Ministry of Health, Labour and Welfare of Japan, and Federal Ministry of Health of Germany. Guilin Pharma has 1 production line for oral solid dosage formulation, 4 production lines for injection and 2 production lines for APIs which obtained PreQualification from the World Health

APIs

Organization (WHO-PQ), as well as 11 formulation products listed in the WHOPQ catalog. Yao Pharma also has 1 production line of oral dosage formulation which obtained the GMP certification from the Canada FDA and the U.S. FDA, and passed site inspection.

INNOVATION FOR GOOD HEALTH

9

Research and Development Fosun Pharma R&D Center

Fosun Pharmaceutical Industry Research Institute

Clinical Research Center

Chemical Drugs Innovation R&D Center (Small molecular chemical drugs)

Biotech Drugs R&D Center (Monoclonal antibody agents drugs)

Generic Drugs R&D Center (Generic drugs with high entry barriers)

Specialized Formulations R&D Center (Sustained and controlled release technology)

Innovation Investment Platform

Medical Diagnosis and Devices R&D Center

4+1 Pharmaceutical R&D platform

“4+1” R&D platform Fosun Pharma always takes independent innovation as the driving force for our development, and improves our R&D system which combines generic and innovative drug development. Fosun Pharma established a unique“4+1” R&D platform focusing on small molecular innovative chemical drugs, large molecular biosimilars, generic drugs with high entry barriers and special formulation technology, and actively follows up the cutting-edge technology in global pharmaceutical industry.

5.64

4.38

R&D Investments and Achievements

unit: RMB100 million

2013

In 2014, the R&D expenditures of Fosun Pharma were RMB564 million, representing an increase of 28.93% year on year; while in the first half of 2015, the expenditures were RMB299 million, representing an increase of 17.75% year on year. Fosun Pharma, with other entities including WuXi PharmaTech, jointly invested in Ambrx Inc., a clinical trial R&D company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics. As of 30 June 2015, Fosun Pharma had 130 pipeline drugs, generic drugs, biosimilars and vaccine projects, 37 projects under clinical trial applications, 13 projects under clinical trial, and 33 projects awaiting official approval for sales.

2014

R&D expenditures

2.99 2.54

unit: RMB100 million

Strategic Alliances for Innovation and R&D Fosun Pharma’s Zhangjiang Innovation and R&D Park focuses on high-end pharmaceutical R&D, in particular the highly promising biotechnology drug, it also plans to build an integrated platform of new drug R&D and pilot test in the future. Fosun Pharma formed the “Fosun Pharma Technology Innovation Strategic Alliance” with prestigious research institutes in China, which is one of the “Industry-Academia-Research Strategic Alliances” initiatives under the national major projects for pharmaceutical innovation and manufacturing. In cooperation with Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Fosun Pharma established a new R&D model and develop three anti-tumor innovative drugs through riskand-benefit sharing scheme.

10

2014H1

2015H1

R&D expenditure in the first half of the year

R&D Team Fosun Pharma owns a national-level technical center and has established highly-efficient international R&D teams in Shanghai, Chongqing, San Francisco and Taipei. As of 30 June 2015, Fosun Pharma has 866 pharmaceutical R&D employees.

Shao Ying

Fu Jiemin

Vice President and Director of

Senior Adviser to President

R&D Center

and a national evaluation expert on new drugs

Deng Jie

Wang Weibo

Scott Liu

Liu Xuejun

Co-head of large molecular

Deputy Director of R&D Center

innovative chemical drugs team,

biosimilars team, a full

and Co-head of specialized

and a talent recruited through

participant in developing

formulations R&D team

the “One-Thousand Talents

Orencia for rheumatoid

Programme” by Organization

arthritis and Vectibix for colon

Department of the CPC Central

cancer

Co-head of generic drugs

Co-head of small molecular

with high entry barriers team

Committee

Lei Huangshu

Zhao Xingdong

Jiang Weidong

Co-head of generic drugs

Co-head of small molecular

Co-head of large molecular

with high entry barriers team

innovative chemical drugs

biosimilars team, led and

team

participated in the R&D of a number of antibody and protein drugs including Vitaxin and Rituxan Biobetter.

INNOVATION FOR GOOD HEALTH

11

Business Overview

03 12

We uphold to our “pursuit of excellence” attitude on products and services, continue to improve our healthcare service and management level through technology advancement, management optimization and service innovation, in order to provide safe, reliable and effective drugs to the public.

Pharmaceutical Manufacturing In 2014, Fosun Pharma’s pharmaceutical manufacturing and R&D segment recorded operating revenue of RMB7.337 billion, representing an increase of 11.43% year on year; while in the first half of 2015, the operating revenue was RMB4.121 billion, representing an increase of 21.58% year on year. In the first half of 2015, the sales of the Fosun Pharma’s major pharmaceutical products maintained rapid growth, among which, the sales of major products in the anti-tumor therapeutic area increased by 43.69% year on year, the sales of major products in the blood system therapeutic area increased by 29.29%, and the sales of major products in the cardiovascular system therapeutic area increased by 24.49% year on year. Rank in China’s major pharmaceutical companies according to IMS CHPA 2015 Q2

NO.4

Pharmaceutical manufacturing and R&D are the core component of Fosun Pharma's strategic development. According to IMS CHPA2015 Q2, Fosun Pharma ranked 4th among major pharmaceutical companies in China. In2014, Fosun Pharma has 17 formulation products and series with over RMB100 million sales, among which: the sales of Compound Aloe Capsules and Xihuang Capsules exceeded RMB100 million for the first time, and the sales of Ao De Jin and Atomolan exceeded RMB500 million.

73.37 65.84 41.21 33.89

Unit: RMB100 million

2013

2014

Operating revenue from pharmaceutical manufacturing and R&D segment

Unit: RMB100 million

2014H1

2015H1

Operating revenue from pharmaceutical manufacturing and R&D segment in the first half of 2015

INNOVATION FOR GOOD HEALTH

13

17

Products with sales over RMB100 million

Therapeutic Areas and Major Products Therapeutic areas

Metabolism and Alimentary Tract

Products Atomolan

Reduced glutathione for Injection / Tablets / Hepatoprotection

Wan Su Lin

Protamine Zinc Insulin Injection / Type II diabetes

Wan Su Ping

Glimepiride Tablets / Type II diabetes

Yi Bao

TCM / Stomach problems, chronic atrophic gastritis and gastrulae

You Li Tong

Hyperuricemia patients with metabolic arthritis symptoms

Xin Xian An

Central Nervous System

You dier

Meglumine Adenosine Cyclophosphate Injection / Coronary artery heart disease, cardiac failure, arrhythmia and sick sinus syndrome Alprostadil Dried Emulsion for Injection / Cardiovascular and cerebrovascular microcirculation, chronic hepatitis Low-molecular-weight Heparin Sodium for Injection / Inhibit coagulation during blood dialysis, and prevent deep vein thrombosis

Ao De Jin

Deproteinized Calf Blood Serum Injection / Improve blood circulation in the brain and neurological deficit caused by nutritional disease (ischemic injury and cranial trauma)

Bang Ting

ARTESUN-PLUS, ARTESUN

Anti-infective

Hyperactivity of heart-liver fire, constipation, abdominal distension & abdominal pain, and irritability & insomnia

Su Ke Nuo

Qi Wei

Blood System

Recombinant Human Erythropoietin for Injection / Anemia caused by renal insufficiency, including dialysis and non-dialysis patients

Mo Luo Dan Compound Aloe Capsules

Cardiovascular

Chemical names / indications

Quetiapine Fumarate Tablets / Negative and positive symptoms of schizophrenia

Hemo-coagulase for Injection / Haemostasis

Artesunate Preparation series / Various malarial diseases

Xi Chang

Cefmetazole Sodium for injection / microorganism-caused infections

Natrii Kalii

Potassium Sodium Pehydroandrographolide Succinate for Injection / viral pneumonia and viral upper respiratory tract infection

Yi Nuo Ni Kang

Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid Tablets II / for a 2-month initial phase intensive treatment of the short term therapy of tuberculosis

Rifampicin Capsules

Eluzer Anti-tumor

Xihuang Capsules

Rifampicin Capsules / tuberculosis & enterococcal infections

Pemetrexed Disodium for Injection/non-small cell lung cancer and malignant pleural mesothelioma Syndrome of toxicity and blood stasis acute, superficial infection, dorsal furuncle swelling, multiple abscess, adenolymphitis, cold abscess

14

Medical Diagnosis and Devices Alma Lasers operates businesses in over

60

countries and regions

Fosun Pharma begins its in-vitro diagnostic business fairly early in China with diversified scope. Our products cover clinical chemistry, clinical immunology, molecular diagnostics (including gene-chip technology and PCR), clinical microbiology etc. We are one of the independent R&D enterprises that produce large volume of in-vitro diagnostic products in China. Owns leading and reputable brands such as “Long March” and “Yaneng” Having invested in domestic and overseas industries, and established strategic cooperation in technology, products and markets Fosun Pharma operates its medical devices businesses mainly through Chindex Medical Limited (CML), with products covering core areas of surgery, aesthetics, imaging, oncology, dental, and transfusion-related devices. Da Vinci surgical robotic system, agented by CML, helps improve surgical operation level in China significantly Alma Lasers is a leading medical and aesthetic device manufacturer globally with businesses covering more than 60 countries and regions including the United States, Germany and Brazil, and has become the market leader of the high-end aesthetic devices. Up to now 5 products have received certification from EU Certification and 3 have received certification from the U.S. FDA Partnered with Foshan Chancheng Central Hospital to establish the laser plastic surgery center, which marks the full launch of the international strategy across Fosun Pharma’s medical and health industry chain

INNOVATION FOR GOOD HEALTH

15

In 2014, the operating revenue of Sinopharm was RMB

200.131

billion

Pharmaceutical Distribution and Retail Sinopharm(stock code: 01099. HK) In 2003, Fosun Pharma co-founded Sinopharm with CNPGC. Sinopharm is the largest pharmaceutical and healthcare products distributor, and leading supply chain service provider in China. It also owns the largest retail pharmacy chain in the country. Sinopharm was listed in Hong Kong in 2009. In 2014, Fosun Pharma and Sinopharm completed the integration of pharmaceutical distribution and retail business, including Fosun Pharmaceutical, Forme Pharmacy and Golden Elephant Pharmacy, so as to optimize resources allocation. Fosun Pharma currently holds 27.83% equity interest in Sinopharm and holds 4 out of the 9 board seats of non-independent directorships. Fosun Pharma benefits from Sinopharm’s extensive distribution network, good industry reputation and comprehensive supply-chain system, and leverages on the synergy with Sinopharm’s distribution network for driving the company’s business growth.

Partnered up with Guahao.com to build up new business model In 2015, Fosun Pharma and Guahao.com signed a strategic cooperation agreement. Both parties will make the best of their superior recourses to carry out in-depth collaboration, among which pharmaceutical e-commerce and medical services are the key areas for cooperation. Guahao.com is the largest Internet-based medical platform in China, coveing 1,420 hospitals, 150,000 experts, with over 82 million registered patients with real-name, the appointment requests for the year of 2015 reached 200 million people.

16

Beijing

United Family Hospital

Fosun Pharma has substantially completed its strategic deployment of healthcare services with high-end healthcare services in the moredeveloped coastal cities featuring "United Family" brand, and oncology specialty and general hospitals in second-tier and third-tier cities.

Tianjin

Suqian Hefei

Shanghai

Foshan Chancheng Hospital Yueyang

Zhongwu Hospital Guangji Hospital

Shenzhen Foshan

Jimin Cancer Hospital

Healthcare Services United Family Hospital, a high-end private hospital with the most popularity and the highest level of internationalization, is the first choice of medical treatment for foreign expatriates, and local wealthy and middle-class group. It has established hospitals and clinics in Beijing, Shanghai, Tianjin and Qingdao. Chancheng Hospital is a large-scale Tier III general hospital that has considerable influence in Foshan and the Pearl River Delta areas. Anhui Jimin Cancer Hospital is the first oncology specialty hospital in Anhui Province. Guangji Hospital in Yueyang, Hunan Province and Zhongwu Hospital in Suqian, Jiangsu Province are both tier II general hospitals and has high reputation in their respective regions. In the first half of 2015, Zhongwu Hospital has started the construction of a habilitation and body-check hospital, and the construction of the “Taizhou Zanyang Medical Care Project” was also launched.

INNOVATION FOR GOOD HEALTH

17

Operation and Management

04 18

We pursue the concept of openness and integration, and advocate for win-win cooperation. Fosun Pharma cooperates with outstanding domestic and foreign entrepreneur teams, working together to create values and share development progress. The entrepreneurial spirit of our team is one of the core competitiveness of Fosun Pharma.

Management Team Our management team has an average of more than 15 years of industry experience, with excellent track record and extensive expertise in the industry.

Mr. Yao Fang

Mr. Li Dongjiu

Mr. Wang Cheng

Mr. Li Chun

Mr. Hongfei Jia

Executive Director Vice Chairman and CEO

Senior Vice President Chairman of Pharmaceutical Commerce and Consumer Goods Management Committee

Senior Vice President Director of Pharmaceutical Industry Management Committee

Senior Vice President

Senior Vice President

Mr. Zhou Biao

Mr. Wu Yifang

Mr. Zhang Xinmin

Mr. Pu Qiangling

Ms. Guan Xiaohui

Senior Vice President Secretary of the Board of Directors and General Manager of the Regulatory Department

Senior Vice President Director of Pharmaceutical Industry Management Committee

Senior Vice President

Senior Vice President Chairman of Medical Device Department

Senior Vice President Chief Finance Officer

Mr. Song Jinsong

Mr. Cui Zhiping

Mr. Zhu Yaoyi

Mr. Wang Kexin

Mr. Bing Li

Senior Vice President Director of Medical Service Management Committee

Vice President

Vice President General Manager of Medical Diagnosis Division

Vice President

Vice President General Manager of the International Department

Mr. Dong Zhichao

Mr. Wang Yao

Mr. Shao Ying

Mr. Chen Yuqing

Ms. Mei Jingping

Vice President Director of R&D Center

Vice President General Manager of Human Resources Department

Vice President General Manager of Strategic Planning Department

Vice President Vice President General Manager of Zhangjiang Innovation General Manager of Medical Devices Division R&D Base

INNOVATION FOR GOOD HEALTH

19

In 2014, the operating revenue wasRMB

12.026

billion

Financial Performance Fosun Pharma proactively transforms itself to adapt to market changes, by implementing innovation strategy, optimizing organizational structure, as well as improving its management system, so as to prompt efficient operations in the company. In 2014, Fosun Pharma recorded operating revenue of RMB12.026 billion, and net profit attributable to shareholders of listed company of RMB2.113 billion, up by 20.30% and 33.51% year on year respectively; in the first half of 2015, Fosun Pharma recorded operating revenue of RMB5.921 billion, and net profit attributable to shareholders of listed company was RMB1.303 billion, up by 6.91% and 28.10% year on year respectively. Fosun Pharma strives to create value for the society and returns to shareholders with integrity. As of the end of 2014, the shareholder's equity increased by 3,111.95% compared to the listing year of 1998. The company has distributed dividends for 15 consecutive years. Fosun Pharma takes tax payable as a pride achievement, the total tax payable was RMB1.268 billion in 2014.

120.26

12.86

21.13 99.96 10.51 15.64

15.83

73.41

7.89

Unit: RMB 100 million

Unit: RMB 100 million

2012

2013

2012

2014

Operating revenue

55.39

2013

2014

Unit: RMB 100 million

2012

Net profit attributable to shareholders of the listed company

59.21 13.03 10.18

Unit: RMB 100 million

2014H1

2015H1

Operating revenue of the first half year

20

Unit: RMB 100 million

2014H1

2015H1

Net profit attributable to shareholders of the listed company in the first half year

2013

2014

Tax payable

Business Integration Case Study We have solid experience and proven track record in acquisition and business integration

Revenue increased by 672% since the merge and acquisition in 2002

672% 205,555 161,005 132,543

Ranks as top 3 in liver protection treatment area In 2002, acquired Yao Pharma, adjusted its development strategies and business philosophy, and established professional teams In 2005, acquired Carelife Pharma to be the raw material manufacturing platform In 2007, set up a Haisiman Pharma, strengthening the construction of marketing teams In 2009, Carelife Pharma and Kaixing Pharma became wholly subsidiaries In 2010, acquired the majority shares of Hexin Pharma, enriching combination of formulation products In 2013, established a joint venture JeilYao Pharma Co., Ltd

Unit: RMB 10,000

2012

2013

2014

Occupies a leading position in areas of endocrinology and metabolism in terms of Revenue increased by 1,029% since the merge and acquisition in 2004

1,029% 180,388 141,440 101,136

market size In 2004, acquired Wanbang Biopharma to conduct business integration, and guided its development In 2006, established Wanbang Jinqiao on the basis of raw material workshop In 2008, established Wanbang Marketing, which is responsible for the sales of Wanbang Pharma’s products In 2009, acquired controlling shares of Folon Pharma, Ltd. and Shanghai Chemo Biopharma to start group development In 2011, acquired the majority of shares of Zhaohui Pharma In 2013, acquired the majority of shares of Wanbang Sainuokang Biochemical In 2014, signed a strategic cooperation agreement with Huanghe Pharma

Unit: RMB 10,000

2012

2013

2014

Alma Lasers’ businesses vary from product R&D and manufacturing to end-user service field Updating laser technology from overseas to serve clients in China at the earliest time possible Successful practice of the concept of “Combining China's Growth Momentum with Global Resources” The full launch of the international strategy across Fosun Pharma’s medical and health industry chain The model, if successfully replicated in the future, will have considerable potential

INNOVATION FOR GOOD HEALTH

21

Our Responsibility

05 22

Fosun Pharma releases CSR report every year, reflecting the harmonious situation between corporation and society; we actively practice corporate social responsibility, and push forward the sustainable development of the whole industry with outstanding enterprises.

2013 2014

RMB1.9 RMB2.36

In 2014, the contribution to society per share increased by 19.49% over 2013.

19.49% Reward the society In 2014, the contribution to society per share was RMB2.36, up by 19.49% over 2013; we have provided more than 250 million artemisinin-based anti-malaria oral medicine globally; we helped over 100 million hepatopaths bring illness under control; we effectively improved health condition of approximately 10 million diabetics every year; since 2010, we have helped 2 million patients suffered from impaired mental functions and other diseases

Environmental health and safety

No.1 Industry rank of the CSR report

Since 2008, our investment for environmental protection construction and reconstruction reached over RMB110 million; In 2014, our water consumption per RMB10,000 decreased 10.76%; power consumption per RMB10,000 decreased 3.95%year on year; energy consumption per RMB10,000 decreased 15.12% year on year

“Future Star” Charity Program The public charity programs of Fosun Pharma is named as “Future Star”. Based on the foundation of the “Future Star” charity education program, Fosun Pharma hopes to perform its social responsibility and make contribution to the society through various channels by supporting education, funding research projects, providing medicine and healthcare community services, donations, disaster relief and so on. Since 2006, Fosun Pharma has undertaken nearly 100 projects on fighting against malaria in Africa in response to the call of the Chinese government. Fosun Pharma set up a volunteer team so as to encourage its employees to participate in social service and public charity undertakings. In 2014, Fosun Pharma donated more than RMB10 million (including materials and personal donations) to society.

Staff Development

In 2014, promotion rate of the company reached

11.48%

Fosun Pharma values the sustainable development of talents, putting forward the talent concept of “Attract talents by development, Unite people with business, Cultivate staff in working and Assess people according to performance”. Currently, the entrepreneurial spirit of our team is one of the core competitiveness of Fosun Pharma. In 2014, the promotion rate of Fosun Pharma reached 11.48%; the total number of employees reached 18,081, up by 7.6% over 2013. Meanwhile, Fosun Pharma continually improves its salary and welfare system. All employees of the group have payment higher than the local minimum wage. In 2014, Fosun Pharma’s cash payment to and on behalf of the employees totaled RMB1.632 billion, an increase of 30.97% from 2013.

INNOVATION FOR GOOD HEALTH

23

Corporate Culture Fosun Pharma always puts a close connection of personal development (Self-improvement), takes good care of social relationship and environment (Teamwork), corporate success (Performance) with contribution to society and country (Contribution to Society).

Fosun Pharma values multicultural integration and overall achievements of the team. We respect diverse background of different enterprises, and emphasize open-minded communication is the key for establishing mutual trust and support, cooperation and unity that fully demonstrate the functions of teamwork.

24

Honors and Awards Industry Status No. 4 “2014 China Pharmaceutical Industry Top 100 Enterprises”

NO.4 No. 1 Evaluation Report of Environmental Responsibility Information Disclosure of Chinese Listed Companies

NO.1

Fosun Pharma ranked No. 16 in the “2014 Top 100 Enterprises of Pharmaceutical Industry in China announced” (by the Ministry of Industry and Information Technology of the PRC) No. 14 in the "Top 100 Enterprises of Pharmaceutical Manufacturing Industry in China for 2014" (by Southern Medicine Economic Institute under China Food and Drug Administration) No. 4 in the “2014 China Pharmaceutical Industry Top 100 Enterprises” (by China Pharmaceutical Industry Association) Admitted to the SSE 180 Index, CSI 300 Index, and the SSE Dividends Index, the SSE Corporate Governance Index, the SSE Private Enterprises Index, the SSE Social Responsibility Index and CCTV Finance 50 Index

Evaluation of CSR In 2014, the Company’s 2013 corporate social responsibility report was rated “annual AA+” by the Rankins CSR Ratings (ranked the third in 665 A-share listed companies altogether), ranked No. 1 in pharmaceuticals industry. (by Rankin’s CSR Ratings) In 2014, in the Evaluation Report of Environmental Responsibility Information Disclosure of Chinese Listed Companies released by Lowcarbon Economics Research Center of Beijing University of Chemical Technology, Fosun Pharma ranked No.1 among all companies participated in the assessment. Awarded the “Best Public Welfare Practice” by the third 2014 China Charity Festival (by Shaanxi TV, China.com(Finance), Huanqiu.com, Gongyi.baidu.com) Awarded the Best CSR 2014 by the China Finance Summit (by more than 30 financial and public media including China.com, Chinanews.com, and Takungpao.com ) Awarded“2013 GoldenBee Corporate Social Responsibility Report • Outstanding Growth Enterprises” (“WTO Guide”, only three enterprises had this honor)

Top 20 “The Most Competitive Listed Pharmaceutical Enterprises”

20

Top

Market Assessment Elected as one of the “Top 50 Enterprises with Integrity Listed on the Main Board of China” (by Association of Chinese Economic Press and IPO123.cn) Elected as one of “The Top 20 Most Competitive Listed Pharmaceutical Enterprises” (by Chinese Pharmaceutical Enterprises Association, Healthcare Executive Magazine and Hejun Consulting) Elected as one of the first “China’s Next Global Giants Top 100 by ACCA” (by the Association of Chartered Certified Accountants) Awarded as the “Best Board of Directors of the Gold Round Table Award” for five consecutive years from 2010-2014 (by “Gold Round Table ” Forum for Boards of Chinese Listed Companies) Awarded the Award of Best Business Model on the Sixth Xin Cai Fu Award Ceremony of “Business Models with the Most Growth Potential” organized by Xin Cai Fu Magazine (by Xin Cai Fu Magazine)

INNOVATION FOR GOOD HEALTH

25

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Building A, Fosun Hi-Tech Park, No.1289 Yishan Road, Xuhui District, Shanghai, P.R. China, 200233 Tel: +86 21 3398 7000 Fax: +86 21 33987020 Postcode: 200233



Designed by Brand & Public Relations Department of Fosun Pharmaceutical (Group) Co., Ltd.

Follow us on WeChat

Data updated from 2015 Interim Report